» Articles » PMID: 28369073

HER2 Signaling Regulates HER2 Localization and Membrane Retention

Overview
Journal PLoS One
Date 2017 Apr 4
PMID 28369073
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

ErbB2/HER2/Neu is a receptor tyrosine kinase that is overexpressed in 25-30% of human breast cancers, usually associated with amplification of the ERBB2 gene. HER2 has no recognized ligands and heterodimers between HER2 and EGFR (ErbB1/HER1) or HER2 and ErbB3/HER3 are important in breast cancer. Unlike other ErbB family members, HER2 is resistant to internalization and degradation, and remains at the cell surface to signal for prolonged periods after it is activated. Although the mechanisms underlying retention of HER2 at the cell surface are not fully understood, prior studies have shown that, in order to avoid internalization, HER2 must interact with the chaperone, HSP90, and the calcium pump, PMCA2, within specific plasma membrane domains that protrude from the cell surface. In this report, we demonstrate that HER2 signaling, itself, is important for the formation and maintenance of membrane protrusions, at least in part, by maintaining PMCA2 expression and preventing increased intracellular calcium concentrations. Partial genetic knockdown of HER2 expression or pharmacologic inhibition of HER2 signaling causes the depletion of membrane protrusions and disruption of the interactions between HER2 and HSP90. This is associated with the ubiquitination of HER2, its internalization with EGFR or HER3, and its degradation. These results suggest a model by which some threshold of HER2 signaling is required for the formation and/or maintenance of multi-protein signaling complexes that reinforce and prolong HER2/EGFR or HER2/HER3 signaling by inhibiting HER2 ubiquitination and internalization.

Citing Articles

HER4 is a high-affinity dimerization partner for all EGFR/HER/ErbB family proteins.

Kumar Singh P, Kim S, Smith A Protein Sci. 2024; 33(10):e5171.

PMID: 39276020 PMC: 11401057. DOI: 10.1002/pro.5171.


HER2 Antibody-Drug Conjugates Are Active against Desmoplastic Small Round Cell Tumor.

Zhang T, Febres-Aldana C, Liu Z, Dix J, Cheng R, Dematteo R Clin Cancer Res. 2024; 30(20):4701-4713.

PMID: 39120576 PMC: 11479846. DOI: 10.1158/1078-0432.CCR-24-1835.


Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance.

Mukund K, Alva-Ornelas J, Maddox A, Murali D, Veraksa D, Saftics A Cancers (Basel). 2024; 16(3).

PMID: 38339304 PMC: 10854992. DOI: 10.3390/cancers16030553.


Intracellular calcium links milk stasis to lysosome-dependent cell death during early mammary gland involution.

Jeong J, Lee J, Talaia G, Kim W, Song J, Hong J Cell Mol Life Sci. 2024; 81(1):29.

PMID: 38212474 PMC: 10784359. DOI: 10.1007/s00018-023-05044-8.


c-Cbl Regulates Murine Subventricular Zone-Derived Neural Progenitor Cells in Dependence of the Epidermal Growth Factor Receptor.

Vogt M, Unnikrishnan M, Heinig N, Schumann U, Schmidt M, Barth K Cells. 2023; 12(19).

PMID: 37830613 PMC: 10572332. DOI: 10.3390/cells12192400.


References
1.
Hogan P, Chen L, Nardone J, Rao A . Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev. 2003; 17(18):2205-32. DOI: 10.1101/gad.1102703. View

2.
Hartman Z, Zhao H, Agazie Y . HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 2012; 32(35):4169-80. PMC: 3538112. DOI: 10.1038/onc.2012.418. View

3.
Zhou X, Agazie Y . The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. Cell Signal. 2011; 24(1):140-50. PMC: 3205337. DOI: 10.1016/j.cellsig.2011.08.015. View

4.
Strehler E . Plasma membrane calcium ATPases as novel candidates for therapeutic agent development. J Pharm Pharm Sci. 2013; 16(2):190-206. PMC: 3869240. DOI: 10.18433/j3z011. View

5.
Chevalier C, Collin G, Descamps S, Touaitahuata H, Simon V, Reymond N . TOM1L1 drives membrane delivery of MT1-MMP to promote ERBB2-induced breast cancer cell invasion. Nat Commun. 2016; 7:10765. PMC: 4764922. DOI: 10.1038/ncomms10765. View